Literature DB >> 28373591

Safety of Temporary Discontinuation of Antihypertensive Medication in Patients With Difficult-to-Control Hypertension.

Martine M A Beeftink1, Nicolette G C van der Sande1, Michiel L Bots1, Pieter A Doevendans1, Peter J Blankestijn1, Frank L J Visseren1, Michiel Voskuil1, Wilko Spiering2.   

Abstract

Successful control of blood pressure relies on identification of secondary causes and contributing factors of hypertension. As antihypertensive medication can interfere with diagnostic investigations, temporary discontinuation of medication is advised. However, there are concerns about the safety of temporary discontinuation of antihypertensive medication in patients with difficult-to-control hypertension. We assessed the occurrence of adverse cardiovascular and cerebrovascular events potentially attributable to temporary discontinuation of antihypertensive medication between February 2010 and March 2016 (n=604) in our Analysis of Complicated Hypertension screening program. A reference group (n=604) was extracted from the SMART study (Second Manifestations of Arterial Disease) cohort (comprising a similar cohort at our hospital in whom medication was not stopped) and individually matched for blood pressure, age, sex, and history of cardiovascular disease. Discontinuation of medication was well tolerated; 62% reported no complaints, 24% had mild discomfort that could be left untreated, and 14% experienced complaints that required prescription of antihypertensive escape medication. Three major adverse events were observed in the Analysis of Complicated Hypertension group between discontinuation of medication and 30 days after restart of medication (event rate=31.2 events per 1000 patient-year). In the reference cohort, 5 cardiovascular events were observed during a similar follow-up period (event rate=51.2 events per 1000 patient-year). In conclusion, discontinuation of antihypertensive medication for the diagnostic evaluation of hypertension does not increase the acute risk of cardiovascular events when performed in a well-controlled setting in specialized hospitals with appropriate protocols for monitoring safety.
© 2017 American Heart Association, Inc.

Entities:  

Keywords:  antihypertensive agents; blood pressure; cardiovascular diseases; hypertension; stroke

Mesh:

Substances:

Year:  2017        PMID: 28373591     DOI: 10.1161/HYPERTENSIONAHA.116.08793

Source DB:  PubMed          Journal:  Hypertension        ISSN: 0194-911X            Impact factor:   10.190


  8 in total

1.  Development of a clinical decision tool to reduce diagnostic testing for primary aldosteronism in patients with difficult-to-control hypertension.

Authors:  Monique E A M van Kleef; Frank L J Visseren; Jan Westerink; Michiel L Bots; Peter J Blankestijn; Yolanda van der Graaf; Wilko Spiering
Journal:  BMC Endocr Disord       Date:  2020-04-29       Impact factor: 2.763

2.  Endothelium-Dependent Vasorelaxant Effect of Prunus Persica Branch on Isolated Rat Thoracic Aorta.

Authors:  Bumjung Kim; Kwang-Woo Kim; Somin Lee; Cheolmin Jo; Kyungjin Lee; Inhye Ham; Ho-Young Choi
Journal:  Nutrients       Date:  2019-08-06       Impact factor: 5.717

3.  The Hyperintense study: Assessing the effects of induced blood pressure increase and decrease on MRI markers of cerebral small vessel disease: Study rationale and protocol.

Authors:  Esther Janssen; Annemieke Ter Telgte; Esmée Verburgt; Joost Ja de Jong; José P Marques; Roy Pc Kessels; Walter H Backes; Marnix C Maas; Frederick Ja Meijer; Jaap Deinum; Niels P Riksen; Anil M Tuladhar; Frank-Erik de Leeuw
Journal:  Eur Stroke J       Date:  2022-05-12

4.  Assessing Outcomes After Adrenalectomy for Primary Aldosteronism - Early is Accurate: Retrospective Cohort Study.

Authors:  Diederik P D Suurd; Wessel M C M Vorselaars; Dirk-Jan Van Beek; Inne H M Borel Rinkes; Wilko Spiering; Gerlof D Valk; Menno R Vriens
Journal:  Ann Surg       Date:  2022-07-27       Impact factor: 13.787

5.  Randomized elimination and prolongation of ACE inhibitors and ARBs in coronavirus 2019 (REPLACE COVID) Trial Protocol.

Authors:  Jordana B Cohen; Thomas C Hanff; Vicente Corrales-Medina; Preethi William; Nicolas Renna; Nelson R Rosado-Santander; Juan E Rodriguez-Mori; Jonas Spaak; Jaime Andrade-Villanueva; Tara I Chang; Alejandro Barbagelata; Carlos E Alfonso; Eduardo Bernales-Salas; Johanna Coacalla; Carlos Augusto Castro-Callirgos; Karen E Tupayachi-Venero; Carola Medina; Renzo Valdivia; Mirko Villavicencio; Charles R Vasquez; Michael O Harhay; Jesse Chittams; Tiffany Sharkoski; James Brian Byrd; Daniel L Edmonston; Nancy Sweitzer; Julio A Chirinos
Journal:  J Clin Hypertens (Greenwich)       Date:  2020-09-16       Impact factor: 3.738

6.  Cardiovascular Disease in the Post-COVID-19 Era - the Impending Tsunami?

Authors:  Usaid K Allahwala; A Robert Denniss; Sarah Zaman; Ravinay Bhindi
Journal:  Heart Lung Circ       Date:  2020-04-16       Impact factor: 2.975

7.  Antihypertensive drugs and risk of COVID-19?

Authors:  Joshua D Brown
Journal:  Lancet Respir Med       Date:  2020-03-26       Impact factor: 30.700

Review 8.  Implications of the COVID-19 Pandemic for Cardiovascular Disease and Risk-Factor Management.

Authors:  Darren Lau; Finlay A McAlister
Journal:  Can J Cardiol       Date:  2020-11-16       Impact factor: 5.223

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.